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a b s t r a c t
Objective:  Evaluate risk factors for colorectal cancer recurrence after surgical treatment. 
Methods:  Sixty-five patients with colorectal adenocarcinoma, stage I and II (TNM), undergoing 
curative-intent surgery and followed for five years were studied. Presence of adjuvant/neo-
adjuvant therapy, tumor differentiation degree, lymphatic and venous vascular infiltration, 
depth of tumor invasion, and disease staging was analyzed, using recurrence relative risk 
ratios for each parameter calculated at two years, after two years and five years of follow up.
Results:  At five years, recurrence was 21.4% (14/65), with equal incidence (10.7%) for the 
separated periods. Only lymphatic and venous vascular infiltration showed statistically 
significant association with recurrence during times analyzed. Relative risk (RR) of recur-
rence was significantly related to the presence of lymphatic infiltration [RR = 6 (1.3 – 28.5) 
p = 0.01] and venous infiltration [RR = 9.5 (2.6 – 34.9) p < 0.001] after two years of follow-up. 
At five years follow-up, only venous infiltration remained with significant relative risk for 
recurrence [RR = 3.9 (1.8 – 8.8) p < 0.001]. In a multivariate analysis, only venous vascular 
infiltration was associated with recurrence [accuracy 81.5% (p < 0.001)].
Conclusion:  In this series, the factors associated with risk of colorectal cancer recurrence 
were the presence of lymphatic and venous vascular infiltration.
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r e s u m o
Fatores de risco para recidiva em pacientes com adenocarcinoma 
colorretal estádio I e II (TNM) submetidos à cirurgia com intenção 
curativa
Objetivo:  Analisar fatores de risco para recidiva de câncer colorretal após tratamento ci-
rúrgico.
Método:  Avaliou-se 65 pacientes com adenocarcinoma colorretal, estadio I e II (TNM), sub-
metidos à cirurgia com intenção curativa, acompanhados por cinco anos após a operação. 
Analisou-se presença de tratamento adjuvante/neoadjuvante, grau de diferenciação do 
tumor, infiltração vascular linfática e venosa, profundidade de invasão tumoral e estadia-
mento da doença, estabelecendo-se para cada um o risco relativo de recidiva aos dois anos, 
após dois anos e aos cinco anos de seguimento. 
Resultados:  Recidiva global em cinco anos foi 21,4% (14/65), com idêntica incidência (10,7%) 
nos períodos separados. Somente as infiltrações vasculares linfáticas e venosas apresen-
taram associação estatisticamente significativa com a recidiva nos períodos de análise. 
Encontrou-se risco relativo (RR) estatisticamente significativo após dois anos relacionados 
à presença de infiltração linfática [RR = 6 (1,3 – 28,5) p = 0,01] e infiltração venosa [RR = 9,5 
(2,6 – 34,9) p < 0,001]. Após cinco anos, apenas a infiltração venosa manteve a significância 
estatística, com risco relativo elevado para ocorrência de recidiva [RR = 3,9 (1,8 – 8,8) p < 
0.001]. Na análise multivariada apenas a presença de infiltração vascular venosa com 81,5% 
de acerto foi associada à recidiva (p < 0.001). 
Conclusão:  Nesta série, os únicos fatores associados com risco de recidiva do câncer color-
retal foram a presença de infiltração vascular linfática e venosa. 
Introduction
Colorectal cancer (CRC) ranks second in mortality in the U.S. 
and in Brazil, second only to lung cancer. The National Insti-
tute of Health reported 141,210 new cases and 49,380 deaths 
in the year 2011.1 In Brazil, according to the National Cancer 
Institute (INCA) data, 30,140 new cases of colon and rectum 
cancer are expected for the year 2012, with a slightly higher 
incidence in women.2 
Although there has been progress in understanding the 
genesis of colorectal tumors, CRC-related  deaths are still 
high, with great impact on public health programs.2 The 
overall median survival at 5 years is around 55% in devel-
oped countries and 40% in developing countries, and can 
reach higher rates.2
Currently, colorectal cancer staging is based on clinico-
pathological staging proposed by the International Union 
Against Cancer (TNM staging system), i.e., depth of tumor 
invasion  into the colon wall, presence of lymph node and 
distant metastases. However, patients with the same stage 
may have different clinical outcomes, indicating that the 
currently used staging may not reflect the actual aggressive-
ness of each individual tumor.3,4
Several efforts have been made regarding the identifica-
tion of the colorectal cancer prognostic factors. This study 
objective was to analyze in a case series of colorectal cancer 
(TNM staging I-II) the relationship between the specific clin-
icopathological factors and recurrence after surgical treat-
ment with curative intent.
Methods
This study was approved by the Human Research Ethics Com-
mittee of the Hospital de Clínicas (HC), Universidade Federal 
do Paraná (UFPR), and registered under the No 82.001/2003-01.
Patients: After reviewing 550 cases of colorectal cancer treat-
ed at the General Surgery and Digestive Surgery centers (HC–
UFPR), from September 1995 to January 2003, 65 patients with 
neoplasia, classified as TNN clinical stage I and II and under-
wenting curative surgical treatment were selected. Exclusion 
criteria were familial adenomatous polyposis, inflammatory 
bowel disease, and postoperative death.
Follow-up: After surgery, patients were followed-up for at 
least five years, according to the following protocol: clinical 
history, physical examination, measurement of blood carci-
noembryonic antigen (CEA), chest X-ray, abdominal ultra-
sound, chest and abdominal CT scans, and colonoscopy. In 
the first year after surgery, follow-up visits were quarterly and 
colonoscopy semiannually; from the second year onward, the 
visits were semiannual and colonoscopy annual. CEA blood 
test, chest X-ray, and abdominal ultrasound were performed 
every three months for the first year and every six months 
after the second year. Chest and abdominal CT scan was per-
formed every six months in the first year and annually from 
the second year onwards.
Study parameters: Data regarding anatomopathological 
parameters, histology, tumor differentiation degree, angio-
lymphatic and angiovenous invasion, depth of tumor inva-
sion into the colon wall, in addition to adjuvant/neoadjuvant 
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therapy used were correlated with the incidence of relapse 
when detected up to two years, after two years, and at five 
years of follow-up.
Statistical Analysis: The measures of central tendency con-
sidered were average, standard deviation, and 95% confidence 
interval for continuous variables and absolute frequencies and 
percentages for categorical variables. The estimated risk was 
performed by calculating the relative risk for variables with 
three levels of classification, always comparing the second lev-
el with the first, then the third level with the first, and finally 
both levels with the first. Multivariate logistic regression and 
discriminant analysis models were used to assess the predic-
tive power for disease recurrence. To estimate the difference 
between variables, Student’s t-test was used for continuous 
variables and chi-square test and Fisher’s exact test for cat-
egorical variables; p values  < 0.05 were considered statistically 
significant.
Results
Patient’s mean age was 58.5 ± 12.6 years (24-79 years), with 
a slight predominance of male (53.3%). Rectal neoplasm ac-
counted for 40% of cases (26), with 40% represented by other 
lesions in the left colon and the remaining 20%  (13) located in 
the right colon. Surgical treatment consisted of anterior recto-
sigmoidectomy or sigmoidectomy in 29 cases (44.7%). Abdom-
inoperineal excision of rectum was performed in 17 patients 
(26.1%). Fifteen patients (23.1%) underwent right colectomy 
and four patients (6.1%) were treated for left colectomy.
Table 1 shows the frequency of the analyzed parameters 
and recurrence occurred during the follow-up times. Adju-
vant/neoadjuvant therapy was used in 44.6% of cases. Grade 
1 histology was predominant (69.3%). Lymphatic infiltration 
overcame venous infiltration (29.2% vs 12.3%), while T3 tu-
mor depth and TNM stage II predominated (64.6%).
Recurrence was observed in 14 patients over the five year 
of follow-up (21.4%), divided equitably (seven cases, 10.7%) be-
tween times up to two years and after two years. Topographi-
cally, the locations with the highest frequency of recurrence 
were the liver and pelvic region, with six cases each (9.2%). 
Recurrence was also seen in the lung and anastomotic line in 
one case each (1.5%) (Table 1).
Regarding relative risk of relapse according to the studied 
parameters, there were no statistically significant differences 
between any of the times studied and the adjuvant/neoadju-
vant therapy used, tumor differentiation degree, depth of tu-
mor invasion, and disease stage (Table 2).
Presence of lymphatic and venous infiltration was associ-
ated with a statistically significant relative risk of recurrence 
after two years of follow up. The risk of recurrence after two 
years of follow-up was six times higher with lymphatic infil-
tration (95% CI = 1.3  –  28.5) than without lymphatic involve-
ment. Similarly, the risk of tumor recurrence after two years 
of follow-up was 9.5 times higher (95% CI = 2.6  –  34.9) with 
venous infiltration than without venous vascular invasion. 
The latter persisted with statistical significance for increased 
risk of recurrence also when analyzing the total follow-up 
time (five years), with a risk of recurrence 3.9 times higher 
(95% CI = 1.8 – 8.8) (Table 2).
Table 1 – Frequency of presented parameters and 
recurrence in the study patients.
Characteristics Values
Adjuvant/neoadjuvant 
therapy
Chemotherapy and/or radiotherapy: 29 
cases (44.6%)
Grade of histological 
differentiation 
Grade I: 45 cases (69.3%)
Grade II: 9 cases (13.8%)
Grade III: 11 cases (16.9%)
Vascular infiltration Lymphatic: 19 cases (29.2%)
Venous: 8 cases (12.3%)
Lymphatic and venous: 6 cases (9.2%)
Depth of tumor invasion T1: 1 case (1.5%)
T2: 22 cases (33.9%)
T3: 42 cases (64.6%)
TNM staging Stage I: 23 cases (35.4%)
Stage II: 42 cases (64.6%)
Recurrence Present: 14 cases (21.4%)
Liver: 6 cases (9.2%)
Pelvic region: 6 cases (9.2%)
Anastomotic line: 1 case (1.5%)
Lung: 1 case (1.5%) 
Time of recurrence:
Up to two years: 7 cases (10.7%)
After 2 years: 7 cases (10.7%)
At 5 years: 14 cases (21.4%)
Table 2 – Relative risk of relapse according to the study parameters.
Study 
parameters
Recurrence
Up to 2 years After 2 years At 5 years
Relative risk p Relative risk p Relative risk p
Adjuvant/
neoadjuvant 
therapy
1.6 (0.4 – 6.8) 0.69 3.1 (0.6 – 14.8) 0.22 2.2 (0.8 – 5.9) 0.13
Degree of tumor 
differentiation
3.6 (0.9 –14.2) 0.08 0.6 (0.1 – 4.7) 0.59 1.3 (0.1 – 4.0) 0.69
Lymphatic 
infiltration
1.0 (0.2 – 4.5) 1.00 6.0 (1.3 – 28.5) 0.01 2.4 (1.0 – 6.0) 0.09
Venous 
infiltration
1.2 (0.2 – 8.6) 1.00 9.5 (2.6 – 34.9) < 0.001 3.9 (1.8 – 8.8) < 0.001
Depth of tumor 
invasion
0.2 (0.01 – 0.09) 1.00 0.2 (0.01 – 0.09) 1.00 0.4 (0.1 – 1.8) 1.00
Disease stage 1.4 (0.3 – 6.5) 1.00 3.5 (0.4 – 27.1) 0.05 3.3 (0.8 – 13.4) 0.11
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Considering relapse as dependent variable, discriminant 
analysis showed that the studied parameter selected with 
the highest discrimination power was the presence of ve-
nous vascular infiltration, with 81.5% of correct classification 
(p < 0.001).
Discussion
In the present study, as often observed in the literature,1,5 
the most frequent tumor location was in the left colon and 
rectum;  histological type was adenocarcinoma; and grade of 
histological differentiation was Grade I.
There was no recurrence in 78% of patients, which can 
be explained by the early clinical stage of tumors (I-II). Re-
currence was more frequent in the liver and pelvic region, 
which is consistent with literature reports.6,7
Diagnosis and treatment of colorectal cancer have evolved 
considerably in recent years, particularly with regard to de-
cisions on limited or complete resection and the type and 
indication of the adjuvant therapy used. In both situations, 
decisions are mainly based on the histopathological findings 
of the resected specimen.8-10 The indication of adjuvant ther-
apy in clinical stages I and II patients remains controversial 
in the literature because, besides the possibility of not in-
creasing the survival of these individuals, it has a high cost 
and may expose them to the adverse effects of QT and RT.8,11
In our series, the evaluation of adjuvant or neoadjuvant 
therapy as a prognostic factor for recurrence showed no sig-
nificant association. This may be evidence that in patients 
with early clinical stage disease the use of adjuvant or neo-
adjuvant treatment does not change the course of disease.
Although adjuvant chemotherapy is indicated for pa-
tients with colorectal cancer with lymph nodes positive for 
malignancy, a small proportion of patients with negative 
nodes have an unfavorable clinical course, and thus adju-
vant therapy could be beneficial for these patients, justify-
ing costs and adverse effects.8,12 Therefore, identification of 
patients at higher risk for local, lymph node, and distance 
metastasis recurrence is critical, regardless of the informa-
tion obtained by the application of the current pathological 
TNM staging system. 
Contrary to what literature often reports, in this series 
we found no association between frequency of tumor re-
currence and degree of differentiation, depth of tumor in-
vasion, and staging.13,14 Coincidentally, the classification of 
these parameters evaluated in this study whose classifica-
tion could not be categorized in a dichotomous (present/
absent), requiring two (TNM staging) or three classes (grade 
of histological differentiation and depth of tumor invasion), 
subdividing the number of patients prior to statistical analy-
sis. Unfortunately, we cannot discard definitively that the 
analysis of these parameters for the associations estimated 
as non-significant may have been a type II error due to the 
sample size. 
The presence of lymphatic and venous vascular infiltra-
tion by neoplastic colorectal cells is described in literature 
as a prognostic factor indicative of more aggressive neo-
plasm.7,15-18 In this study, 29% of patients had lymphatic vas-
cular infiltration and 12% had venous infiltration. Moreover, 
there was a statistically significant association between 
venous or lymphatic infiltration and tumor recurrence rate 
measured at follow-up.
When we stratified the time of global recurrence, as-
sessed at five years follow-up in two different times (up to 
two years and after two years recurrence), we found similar 
behavior of lymphatic and venous infiltration according to 
the sub-period analyzed (Table 2). Both parameters (venous 
and lymphatic infiltration) did not reach statistical signifi-
cance when studied for association with early relapse within 
two years. On the other hand, both parameters were signifi-
cantly associated with tumor recurrence after the third year 
of follow up. We believe that this fact has important clini-
cal implications relevant to current and future strategies of 
postoperative follow-up of patients undergoing colorectal 
cancer surgery. We could ask, for example, to patients at 
follow-up (with known high risk of recurrence) the reasons 
for the infrequency, except from the third year of follow up. 
Are frequency and the means currently available to detect 
recurrences suitable for the earlier periods of follow-up? Is 
there a different clinical profile among patients with early 
recurrence compared to others?
In this series, the predictive factors of recurrence in mul-
tivariate analysis revealed vascular venous infiltration as the 
only factor capable of predicting recurrence alone with sta-
tistical significance (p < 0.001).
Currently, the biological behavior of malignant colorectal 
neoplasm still surpasses the ability to predict recurrence pa-
rameters of known value and used for evaluation and char-
acterization of clinical placements.
Conclusion
In this work, it was possible to concluded that among the 
clinicopathological factors analyzed, the ones associated with 
risk of recurrence were lymphatic and venous vascular infil-
tration by tumor cells; nevertheless, only after two years of 
follow-up.
Further studies with new criteria to predict early relapse 
are still needed in order to have an even better performance 
in colorectal cancer follow-up.
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